Clinical trials: Stage IIIC
Male Breast Cancer, Stage IIIA Breast Cancer
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
This phase I/II trial is studying the side effects and best dose of oblimersen when given together with doxorubicin and docetaxel and to see how well they work in treating women with metastatic or locally advanced breast cancer.
- Conditions
- Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT00063934
- Testing
- oblimersen sodium, doxorubicin hydrochloride, docetaxel
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma cells.
- Conditions
- Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
- Trial name
- NCT02748564
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
This phase II trial studies how well panitumumab, carboplatin and paclitaxel work in treating patients with newly diagnosed triple negative breast cancer that is limited to the breast and possibly to the nearby lymph nodes…
- Conditions
- Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7
- Trial name
- NCT02593175
- Testing
- Carboplatin, Paclitaxel, Panitumumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
HER2/Neu Negative, No Evidence of Disease
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
This phase I trial studies the side effects and best dose of a vaccine therapy in preventing cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast…
- Conditions
- HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer
- Trial name
- WOKVAC (NCT02780401)
- Testing
- Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer, Rectal Cancer
Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
This phase II, randomized pilot trial studies the effect of the consumption of foods made with resistant starch compared to foods made with corn starch on biomarkers that may be related to colorectal cancer progression in stage…
- Conditions
- Colon Cancer, Rectal Cancer, Cancer Survivor, Colorectal Adenocarcinoma
- Trial name
- NCT03781778
- Testing
- Dietary Intervention (resistant starch), Dietary Intervention (regular starch), Questionnaire Administration
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
RATIONALE: Vaccines may make the body build an immune response and decrease the recurrence of breast cancer. PURPOSE: Pilot trial to study the effectiveness of vaccine therapy in treating patients who are at high risk for breast…
- Trial name
- NCT00030823
- Testing
- Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Radiation Toxicity, Recurrent Breast Cancer
Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy
This phase II trial is studying how well alkaline water works in reducing skin toxicity in women with breast cancer undergoing radiation therapy.
- Conditions
- Radiation Toxicity, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01487954
- Testing
- alkaline water, distilled water, external beam radiation therapy (EBRT)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Case Comprehensive Cancer Center
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
This phase II trial studies how well atorvastatin works in treating patients with stages IIb-III triple negative breast cancer who did not achieve a pathologic complete response to neoadjuvant chemotherapy.
- Conditions
- Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT03872388
- Testing
- Atorvastatin, Capecitabine
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well pembrolizumab works when given in combination with carboplatin and paclitaxel in treating patients with stage III-IV ovarian, primary peritoneal, or fallopian tube cancer.
- Conditions
- Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7
- Trial name
- NCT02520154
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer that can be removed by surgery.
- Conditions
- Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
- Trial name
- NCT00770809
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel
- Where
- 318 sites in United States, Puerto Rico
- Volunteers
- 305 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00702884
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Tony Bekaii-Saab
Melanoma
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered GM-CSF in patients with unresectable Stage IIIb, IIIc and Stage IV melanoma.
- Trial name
- NCT00769704
- Testing
- Talimogene laherparepvec, GM-CSF
- Where
- 83 sites in United States, Canada and 2 more
- Volunteers
- 437 people
- Sponsor
- BioVex Limited
Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer
Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
This pilot, phase II trial studies the side effects and how well paclitaxel given into the vein and carboplatin given directly into the abdominal cavity (intraperitoneally) followed by radiation therapy work in treating patients…
- Conditions
- Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer
- Trial name
- NCT02112552
- Testing
- Paclitaxel, Carboplatin, 3-Dimensional Conformal Radiation Therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer, Male Breast Cancer
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00470301
- Testing
- tipifarnib, paclitaxel, doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor Negative, Estrogen Receptor Positive
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
This phase II trial is studies how well Akt inhibitor MK2206 works in treating patients with stage I-III breast cancer that can be removed by surgery.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01319539
- Testing
- Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
- Trial name
- NCT00289016
- Testing
- Talimogene Laherparepvec
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 50 people
- Sponsor
- BioVex Limited
Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
This randomized phase II trial studies how well regorafenib works in treating patients with cancer of the esophagus or gastroesophageal junction that has spread from where it started to nearby tissue or lymph nodes and have…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma
- Trial name
- NCT02234180
- Testing
- Regorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Academic and Community Cancer Research United
Breast Cancer
Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NRR (NCT00006110)
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Stage IIIB Melanoma, Stage IIIC Melanoma
Dinaciclib in Treating Patients With Stage III-IV Melanoma
This is a phase I/II trial is studying the side effects and best dose of dinaciclib and to see how well it works in treating patients with advanced melanoma.
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT01026324
- Testing
- dinaciclib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)